A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

Cancer Cell
John Y LiSteven R Coats

Abstract

Antibody-drug conjugate (ADC) which delivers cytotoxic drugs specifically into targeted cells through internalization and lysosomal trafficking has emerged as an effective cancer therapy. We show that a bivalent biparatopic antibody targeting two non-overlapping epitopes on HER2 can induce HER2 receptor clustering, which in turn promotes robust internalization, lysosomal trafficking, and degradation. When conjugated with a tubulysin-based microtubule inhibitor, the biparatopic ADC demonstrates superior anti-tumor activity over ado-trastuzumab emtansine (T-DM1) in tumor models representing various patient subpopulations, including T-DM1 eligible, T-DM1 ineligible, and T-DM1 relapsed/refractory. Our findings indicate that this biparatopic ADC has promising potential as an effective therapy for metastatic breast cancer and a broader patient population may benefit from this unique HER2-targeting ADC.

References

Feb 15, 2003·Trends in Cardiovascular Medicine·Alistair N GarrattCarmen Birchmeier
Mar 22, 2003·Experimental Cell Research·H Steven Wiley
Sep 24, 2004·Molecular Biology of the Cell·Cary D AustinRichard H Scheller
Feb 3, 2005·Proceedings of the National Academy of Sciences of the United States of America·Lilach M FriedmanYosef Yarden
Jun 8, 2007·Cancer Letters·Yelena V Kovtun, Victor S Goldmacher
Feb 22, 2008·Histochemistry and Cell Biology·Kirstine RoepstorffBo van Deurs
Nov 18, 2008·Cancer Research·Gail D Lewis PhillipsMark X Sliwkowski
Feb 17, 2009·Proceedings of the National Academy of Sciences of the United States of America·Tsipi Ben-KasusMichael Sela
Mar 11, 2010·Expert Opinion on Biological Therapy·Elda TagliabueSerenella M Pupa
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Jamie B SpanglerK Dane Wittrup
Dec 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard A BurrisJoyce A O'Shaughnessy
Mar 10, 2011·Proceedings of the National Academy of Sciences of the United States of America·Joan T GarrettCarlos L Arteaga
Oct 2, 2012·The New England Journal of Medicine·Sunil VermaUNKNOWN EMILIA Study Group
Oct 10, 2012·Annual Review of Medicine·Eric L Sievers, Peter D Senter
Oct 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gail D Lewis PhillipsMark X Sliwkowski
Nov 26, 2013·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Robert Roskoski
Feb 5, 2014·Journal of Biomolecular Screening·Wei ZhaoHarry Yang
Jun 27, 2014·Journal of Medicinal Chemistry·John M Lambert, Ravi V J Chari
Jul 23, 2014·The Breast : Official Journal of the European Society of Mastology·Antonio Llombart-CussacJavier Cortes
Nov 6, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hirdesh UppalVanitha Ramakrishnan

❮ Previous
Next ❯

Citations

Jun 22, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Pamela ThompsonNazzareno Dimasi
Nov 12, 2016·Trends in Pharmacological Sciences·James R KintzingJennifer R Cochran
Jun 30, 2016·Biopolymers·Daniël LeenheerChristopher John Hipolito
Dec 17, 2016·International Journal of Molecular Sciences·Quanxia LvGe Zhang
Dec 31, 2016·International Journal of Molecular Sciences·Fa YangWeijun Qin
Jan 27, 2017·Journal of Immunotherapy·Gennaro RiccioClaudia De Lorenzo
Mar 1, 2017·Molecular Pharmaceutics·Nazzareno DimasiChangshou Gao
Aug 2, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Hao ChenWei Li
Apr 20, 2018·The Journal of Biological Chemistry·Vaheh OganesyanWilliam Dall'Acqua
Feb 24, 2018·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Osamu Kusano-AraiTakao Hamakubo
Oct 26, 2018·Expert Opinion on Investigational Drugs·Alexis D LealWells A Messersmith
Feb 8, 2018·Journal of Experimental & Clinical Cancer Research : CR·Cécile Chalouni, Sophia Doll
Oct 26, 2018·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Ying FuMitchell Ho
Feb 17, 2019·Clinical Pharmacology and Therapeutics·Johannes DuellSaar Gill
Apr 2, 2019·Current Treatment Options in Oncology·Noam PondéMartine Piccart
Dec 2, 2017·Nature Reviews. Drug Discovery·Paul J Carter, Greg A Lazar
Jun 9, 2019·Nature Reviews. Drug Discovery·Aran F LabrijnPaul W H I Parren
Jun 20, 2019·Journal of Cellular Physiology·Sajad YaghoubiMeghdad Abdollahpour-Alitappeh
Jan 7, 2020·Médecine sciences : M/S·Alain BeckNicolas Joubert
Mar 21, 2020·SLAS Discovery·Laurence Gauzy-LazoMarie-Priscille Brun
Mar 11, 2020·Expert Review of Clinical Pharmacology·Edward R Sauter
May 5, 2016·Physiological Reviews·Andreas WickiGongda Xue
Sep 28, 2016·Journal of Pharmacokinetics and Pharmacodynamics·Aman P SinghDhaval K Shah
Mar 18, 2017·Nature Reviews. Drug Discovery·Alain BeckNathalie Corvaïa
Mar 27, 2019·Therapeutic Advances in Medical Oncology·Sonia Pernas, Sara M Tolaney
Mar 8, 2019·International Journal of Molecular Sciences·Gabriel RinnerthalerRichard Greil
Mar 28, 2020·American Society of Clinical Oncology Educational Book·Shalini Makawita, Funda Meric-Bernstam
Jul 14, 2020·Current Opinion in Oncology·Eleonora NicolòGiuseppe Curigliano
May 10, 2019·Frontiers in Pharmacology·Haichao TangYing Jin
Jul 31, 2020·Nature·Steven M BanikCarolyn R Bertozzi
Oct 7, 2017·Protein Engineering, Design & Selection : PEDS·Hok Seon KimChristoph Spiess
Aug 23, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Eshita Khera, Greg M Thurber
Jun 19, 2019·Scientific Reports·Satoshi KawanoYoshito Kishi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

The New England Journal of Medicine
Sunil VermaEMILIA Study Group
Current Medical Research and Opinion
Baris BoyrazKadri Altundag
Journal of the Advanced Practitioner in Oncology
Rena Callahan
© 2022 Meta ULC. All rights reserved